A changing world for DCvax: a PSMA loaded autologous dendritic cell vaccine for prostate cancer
Northwest Therapeutics' DCvax-prostate consists of autologous dendritic cells (DCs) loaded with prostate-specific membrane antigen (PSMA) peptides, administered intravenously. Phase I-II testing, a decade ago, showed clinical benefit and immunological response in some patients. More recently DCvax brain, a product using a similar DC platform showed encouraging Phase I-II results and sipleucel-T, a prostatic acid phosphatase (PAP)-directed DC immunotherapy had positive Phase III results.
Version: za2963e q8za3 q8zbf q8zc4 q8zd2 q8ze3 q8zf7 q8zgb